Skip to main content

Table 1 Patient characteristics

From: Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study

Stroke population after matching

VKA (n = 347,240)

DOAC (n = 347,240)

SMD

Before

After

Age

Mean(± SD)

75.78 (± 8.84)

75.70 (± 9.85)

0.03

0.01

Median

77

77

  

Age distribution (%)

18–36

0.09

0.19

  

37–54

2.14

3.22

  

55–72

27.53

27.43

  

73+

70.24

69.16

  

Female sex (%)

 

52.02

53.00

− 0.07

− 0.02

CHA2DS2-VASc score

Mean (± SD)

4.45 (± 1.70)

4.39 (± 1.77)

0.12

0.04

Median

4

4

  

CHA2DS2-VASc score distribution (%)

0–1

3.77

5.29

  

2–3

25.12

25.28

  

4–5

44.74

43.23

  

6–7

22.41

22.02

  

8–9

3.96

4.18

  

Charlson Comorbidity Index

Mean (± SD)

2.92 (± 2.63)

2.84 (± 2.63)

0.09

0.03

Median

2

2

  

Charlson Comorbidity Index distribution (%)

0–4

76.76

77.66

  

5–9

20.91

20.03

  

10–15

2.24

2.24

  

15+

0.16

0.14

  

Number of distinct prescriptions (ATCs)

Mean (± SD)

12.50 (± 5.72)

12.43 (± 5.78)

0.05

0.01

Median

12

11

  

Number of prescriptions (ATCs)

Mean (± SD)

35.43 (± 21.17)

34.88 (± 21.43)

0.08

0.03

Median

31

30

  

Number of diagnoses (ICD codes)

Mean (± SD)

28.21 (± 15.39)

27.97 (± 15.52)

0.04

0.02

Median

26

25

  

Prescribed medicines (%)

Antiarrhythmic agents

90.47

90.41

0.01

0.00

Antihypertensive drugs

80.94

80.39

0.06

0.01

Antiplatelet drugs

25.14

25.56

− 0.03

− 0.01

Corticosteroids (systemic use)

14.83

15.09

− 0.03

− 0.01

Fondaparinux

0.78

0.68

0.02

0.01

Heparins

27.02

23.44

0.36

0.07

Insulin

10.98

10.57

0.04

0.01

Lipid-lowering agents

47.61

46.35

0.09

0.03

NSAIDs

40.00

40.79

− 0.05

− 0.02

Oral anti-diabetic drugs

20.12

20.09

0.01

0.00

Peptic ulcer/reflux disease

49.88

50.32

− 0.04

− 0.01

SSRIs

5.39

5.62

− 0.04

− 0.01

Comorbidities (%)

Alcohol abuse/addiction

2.33

2.42

− 0.02

− 0.01

Bleeding extracerebral

5.53

5.11

0.05

0.02

Bleeding GI

5.81

5.68

0.02

0.01

Bleeding intracerebral

0.45

0.48

− 0.02

0.00

Cancer

19.77

19.80

0.00

0.00

Coagulopathy

1.81

1.63

0.03

0.01

Congestive heart failure

28.97

27.18

0.12

0.04

COPD

16.04

15.79

0.02

0.01

Coronary heart disease

40.67

38.72

0.13

0.04

Diabetes

38.69

37.84

0.05

0.02

Diverticulitis

10.66

10.80

− 0.01

0.00

Embolism systemic

0.80

0.70

0.03

0.01

Embolism venous

5.15

4.75

0.05

0.02

Esophageal varices

0.21

0.21

0.00

0.00

Hypertension

88.14

87.79

0.05

0.01

Ischemic stroke

8.62

8.41

0.02

0.01

Liver disease

13.48

13.31

0.02

0.00

Nicotine use/dependence

4.44

4.51

− 0.01

0.00

Renal disease

14.88

13.31

0.12

0.04

Upper GI

25.97

26.25

− 0.03

−  0.01

Vascular disease

21.99

21.54

0.04

0.01

Vascular dementia

1.87

1.99

− 0.05

− 0.01

Venous malformation

1.85

1.64

0.04

0.02

  1. VKA vitamin K antagonist, DOAC direct oral anticoagulant, SMD standardized mean difference, SD standard deviation, ATCs Anatomical Therapeutic Chemical classification codes